Clinical study of co-trimazine in urinary tract infections: a comparison with nitrofurantoin.
Co-trimazine, a new preparation of sulphadiazine and trimethoprim, was compared with nitrofurantoin in a double-blind trial on patients with acute urinary tract infections. Co-trimazine had a bacteriological cure rate of 95% as compared to 88% for nitrofurantoin. There were no statistically significant differences in laboratory findings or in clinical side-effects between the two laboratory findings or in clinical side-effects between the two preparations. It was concluded that co-trimazine might constitute a valuable addition amongst drugs suitable for treatment of acute urinary tract infections.
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009582:Nitrofurantoin / Q000009:adverse effects / Q000627:therapeutic use*; D013411:Sulfadiazine / Q000009:adverse effects / Q000627:therapeutic use*; D014295:Trimethoprim / Q000009:adverse effects / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D004338:Drug Combinations; D013411:Sulfadiazine; D009582:Nitrofurantoin; D014295:Trimethoprim